Medication info

Mavilque Injection (Ibandronic Acid Sodium Monohydrate)

Prescription medicationInjectionsIntravenous injection
Ingredient · strength
Ibandronate Sodium Monohydrate›3.375mg / 1 prefilled syringe
Manufacturer / importer
YuYu Pharmaceutical Co., Ltd.
Appearance
An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, equipped with a single-use injection needle.
Packaging
1 prefilled syringe (3mL/pre-filled syringe)
Approval status
Active

MFDS item code 201307917 · Notified 2013.06.28 · Insurance code 644501971

Summary

Main use
Treats osteoporosis in postmenopausal women
Who receives it
Adults · Children
Adult administration
Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. Use of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience is insufficient. Elderly patients No dosage adjustment is necessary.
Child administration
Efficacy and safety have not been studied in children 18 years of age or younger.

Ingredients

Manufacturer
YuYu Pharmaceutical Co., Ltd.

Efficacy & effects

Treats osteoporosis in postmenopausal women

  • Osteoporosis
View approved original text

This medication is used for the treatment of osteoporosis in postmenopausal women.

How it is given

Adult administration

Administer 3mg by intravenous injection over 15 - 30 seconds once every 3 months. Patients should take calcium and vitamin D as supplements. If a dose is missed on the scheduled dosing date, administer the injection as soon as possible and continue regular dosing at 3-month intervals from that date. Patients with hepatic impairment No dosage adjustment is necessary. Patients with renal impairment No dosage adjustment is necessary in patients with mild or moderate renal impairment whose serum creatinine is 200 µmol/L(2.3mg/dL) or less or whose creatinine clearance is 30ml/min or more. Use of this drug is not recommended in patients whose serum creatinine exceeds 200 µmol/L(2.3mg/dL) or whose creatinine clearance is less than 30ml/min, because clinical experience is insufficient. Elderly patients No dosage adjustment is necessary.

Child administration

Efficacy and safety have not been studied in children 18 years of age or younger.

Precautions

This medication must be administered intravenously, and great care must be taken to avoid administration into an artery or around a vein, as tissue damage may occur. It should not be used in patients with a known allergy to this medication or any of its components, or in untreated hypocalcemia patients. Use of this medication may result in gastrointestinal adverse reactions such as gastritis, diarrhea, abdominal pain, indigestion, nausea, and constipation. Musculoskeletal pain, joint pain, and muscle pain may occur, and some patients may experience systemic symptoms such as influenza-like symptoms, fatigue, headache, and rash. Rarely, during the administration of this drug, allergic reactions such as vasculitis, hypersensitivity, skin rash, angioedema, and urticaria may occur, so caution is advised. Bisphosphonate medications can cause serious side effects like osteonecrosis of the jaw, so it's advisable to have a dental check-up before taking this medication and to avoid excessive dental treatment during therapy. Long-term use of this medication may lead to atypical fractures in the femur and other bones; if there is pain in the leg or groin, immediate consultation with a healthcare professional is required. This medication can temporarily lower serum calcium levels, so adequate intake of calcium and vitamin D should be ensured before and during treatment, and it should be used only after hypocalcemia is treated. Patients with poor kidney function or taking other medications that may affect the kidneys should have regular check-ups to monitor their condition. It is recommended that pregnant or breastfeeding women do not use this medication, as its safety has not been established. In case of overdose, the renal and hepatic functions may be affected; therefore, immediate monitoring and appropriate treatment at a hospital should be sought if overdose is suspected. This medication should not be mixed with calcium-containing solutions or other intravenous medications and must be administered solely via intravenous injection. After use, do not reuse the syringe or needle, and dispose of them safely, keeping them out of reach of children.

Side effects

Gastritis, diarrhea, abdominal pain, indigestion, nausea, constipation, musculoskeletal pain, joint pain, muscle pain, influenza-like illness, fatigue, headache, rash, bone pain, weakness, injection site reaction, phlebitis, thrombophlebitis, hypersensitivity reaction, angioedema, facial swelling, edema, urticaria, osteonecrosis of the jaw and external auditory canal, uveitis, episcleritis, scleritis, anaphylactic reaction, shock, exacerbation of asthma, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical electronic hand fracture, intertrochanteric femoral fracture, dizziness, optic nerve atrophy, lower motor neuron lesion, tremor, unspecified gastrointestinal disorder, benign gastrointestinal neoplasm, toothache, hyperventilation, cough, dyspnea, laryngitis, vaginitis, menopausal symptoms, multiple organ failure, death, insomnia, anxiety, tinnitus, hearing loss, hypothyroidism, lipoma, ocular hemorrhage, heart failure, urinary disorders, hematuria, skin desquamation, sensory decrease, acute renal failure

Not everyone experiences these, and they can vary from person to person.

Storage

Store this medication in a sealed container to prevent air or moisture ingress, and it's best to keep it at room temperature between 1°C and 30°C. Proper storage can ensure the safety of the medication's efficacy.

Appearance and packaging

Appearance

An injection in a colorless, transparent solution contained in a colorless, transparent glass prefilled syringe, equipped with a single-use injection needle.

Package unit

1 prefilled syringe (3mL/pre-filled syringe)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.